- Home
- SXTP vs INDP Comparison
SXTP vs INDP Comparison
Compare SXTP & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- INDP
- Stock Information
- Founded
- SXTP 2010
- INDP 2000
- Country
- SXTP United States
- INDP United States
- Employees
- SXTP N/A
- INDP N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- INDP Health Care
- Exchange
- SXTP Nasdaq
- INDP Nasdaq
- Market Cap
- SXTP 5.9M
- INDP 6.0M
- IPO Year
- SXTP 2023
- INDP N/A
- Fundamental
- Price
- SXTP $1.44
- INDP $2.37
- Analyst Decision
- SXTP Buy
- INDP Strong Buy
- Analyst Count
- SXTP 2
- INDP 2
- Target Price
- SXTP $3.00
- INDP $238.00
- AVG Volume (30 Days)
- SXTP 69.3K
- INDP 218.3K
- Earning Date
- SXTP 11-13-2025
- INDP 11-11-2025
- Dividend Yield
- SXTP N/A
- INDP N/A
- EPS Growth
- SXTP N/A
- INDP N/A
- EPS
- SXTP N/A
- INDP N/A
- Revenue
- SXTP $984,494.00
- INDP N/A
- Revenue This Year
- SXTP $81.41
- INDP N/A
- Revenue Next Year
- SXTP $95.63
- INDP N/A
- P/E Ratio
- SXTP N/A
- INDP N/A
- Revenue Growth
- SXTP 128.70
- INDP N/A
- 52 Week Low
- SXTP $1.22
- INDP $2.22
- 52 Week High
- SXTP $12.45
- INDP $58.24
- Technical
- Relative Strength Index (RSI)
- SXTP 52.52
- INDP 21.88
- Support Level
- SXTP $1.36
- INDP $2.22
- Resistance Level
- SXTP $1.45
- INDP $2.86
- Average True Range (ATR)
- SXTP 0.08
- INDP 0.62
- MACD
- SXTP 0.02
- INDP -0.13
- Stochastic Oscillator
- SXTP 73.77
- INDP 3.39
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.